Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: A randomized phase III study

China Omalizumab Study Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)319-328
Number of pages10
JournalAllergy, Asthma and Immunology Research
Volume8
Issue number4
DOIs
StatePublished - 2016
Externally publishedYes

ASJC Scopus Subject Areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Keywords

  • Allergy and immunology
  • Asthma
  • China
  • Omalizumab
  • Quality of life

Cite this